Roundup Lawsuits Overshadow Pharma Growth At Bayer
Xarelto And Eylea Continue To Climb
Executive Summary
Pharmaceutical sales hit €4.35bn helped by a strong showing in China but as the number of glyphosate plaintiffs in the US jumps to 42,700, the German group's priority is sorting out Monsanto.
You may also be interested in...
Staying Diversified, Bayer Sees Opportunities In Digital Innovation
Despite its Monsanto woes, Bayer is sticking with its diversified portfolio, and is branching out into patient-facing digital health services.
Label Battles: Beovu And Eylea Contest Begins In AMD
Shares in Eylea-maker Regeneron slid after FDA approved Novartis's competing VEGF inhibitor for treating AMD, but some observers said investors had overreacted.
Anxious Investors Relieved At Bayer’s Fresh Monsanto Litigation Strategy
Bayer has taken steps to address the concerns of its stockholders by pulling together a legal team for its ongoing US glyphosate litigation, and bringing on board Merck’s Vioxx lawyer.